Yan Ke Xue Bao (monthly, ISSN: 1000-4432; CN: 44-1119/R) and its English version, Eye Science (quarterly, ISSN: 3005-9984; e-ISSN: 3005-9992), were launched in 1985. These are international medical academic journals overseen by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and published and distributed by the Zhongshan Ophthalmic Center of Sun Yat-sen University. Professor Haotian Lin from the Zhongshan Ophthalmic Center, Sun Yat-sen University, serves as the Editor-in-Chief, while Professor Zhenzhen Liu from the same center holds the position of Executive Editor-in-Chief.

Yan Ke Xue Bao is dedicated to advancing the global integration of ophthalmology with multidisciplinary innovations in strategies for the prevention and treatment of eye diseases. It covers the latest research developments in related fields, including, but not limited to, basic and clinical research in ophthalmology, innovative treatments and translational applications for eye diseases, and ophthalmic epidemiology.

Yan Ke Xue Bao is indexed in major domestic and international databases such as the Global OA Journal Index (OAJ), EuroPub (European Academic Publishing Center Database), Chemical Abstracts (CA), ICI Journals Master List (Copernicus Selected Journals Database), Lighthouse Scholar, China National Knowledge Infrastructure (CNKI), China Core Journals (Selected) Database (Wanfang), the Chinese Scientific and Technical Journals Database (VIP) and China Open Access Journal (COAJ). It is also recognized as an innovative service demonstration unit within the "Professional Content Knowledge Aggregation Service Platform," a national key research and development initiative.

Overview of Zhongshan Ophthalmic Center

Zhongshan Ophthalmic Center of Sun Yat-sen University is the only specialized ophthalmic hospital directly managed by the National Health Commission of China. It serves as the affiliated institution of the only National Key Laboratory for Ophthalmological Disease Prevention and Control. The Center is a national leader in ophthalmological innovation, making globally recognized contributions in areas such as regenerative ophthalmic medicine, bioinformatics, and medical artificial intelligence. Notably, the Center pioneered the in-situ regeneration of the lens using endogenous stem cells, a breakthrough published in Nature in 2016 and recognized by Nature Medicine as one of the "Top Eight Global Medical Advances" of the year, the first such honor for China's medical community. The research on myopia in adolescents received significant attention from President Jinping Xi, who issued an important directive in response. The Center's discovery that increased outdoor activities can effectively prevent myopia in adolescents was published in JAMA and has been incorporated into myopia prevention programs by both the World Health Organization (WHO) and Chinese government ministries. In addition, the Center has innovated in clinical applications of ophthalmic AI and successfully developed a new cataract drug, achieving a record-breaking technology transfer deal worth CNY 1.38 billion. The Center has won 11 National Science and Technology Progress Awards as the leading institution.

Zhongshan Ophthalmic Center is the most internationally influential ophthalmic institution in China. It is the only WHO collaborating center for ophthalmology in China and hosts the Asia-Pacific Academy of Ophthalmology, marking the first international medical academic organization based in Mainland China. The Center is also a member of ophthalmic research alliances in China, the UK, and the US.

Submission Turnaround Time:

Initial Review: 3 days

Peer Review: 2 weeks

Online Publication: Within 1-week post-acceptance

Formal Publication: Between 1 to 3 months post-acceptance, with original research articles receiving publication priority